IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. 
Calcitonin Gene Related Peptide-Induced Headache in Patients With Familial Hemiplegic Migraine Type 1 and 2.
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
| Condition | Intervention |
|---|---|
| Familial Hemiplegic Migraine | Drug: CGRP |
| Study Type: | Interventional |
| Study Design: | Allocation: Non-Randomized Intervention Model: Parallel Assignment Masking: Single Blind Primary Purpose: Educational/Counseling/Training |
| Official Title: | Calcitonin Gene Related Peptide-Induced Headache in Patients With Familial Hemiplegic Migraine Type 1 and 2. |
- headache and associated symptoms
- blood flow velocity of the middle cerebral artery
- diameter of the superficial temporal artery
- MAP
- HR
| Estimated Enrollment: | 20 |
| Study Start Date: | July 2006 |
| Estimated Study Completion Date: | October 2006 |
Calcitonin Gene Related Peptide (CGRP) induces migraine attacks indistinguishable from spontaneous attacks in approximately 50% of migraine sufferers. Treatment of spontaneous migraine attacks with an antagonist to CGRP is effective in many patients. These data show that CGRP is involved in both initiation and maintenance of migraine attack.
The consequence of migraine gene mutations on relevant migraine pathways has never been tested. The aim of the present study is to explore functional consequences of migraine gene mutations on their responses to CGRP infusion. The project will improve our understanding of the neurobiology of migraine and stimulate development of new treatment targets.
Eligibility| Ages Eligible for Study: | Child, Adult, Senior |
| Sexes Eligible for Study: | All |
| Accepts Healthy Volunteers: | Yes |
Inclusion Criteria:
Patients: Diagnosis of familial hemiplegic migraine (IHS-classification criteria) caused by mutations in the CACNA1A gene and the ATP1A2 gene.
Controls: Healthy volunteers
Exclusion Criteria:
Controls: No primary headache in their own history 2) Patients and controls:
- A history of cerebrovascular disease and other CNS- disease
- A history of serious somatic and mental disease
- A history suggesting ischaemic heart disease
- A history of hypo- or hypertension
- Daily intake of medication apart from oral contraceptives
- Abuse of alcohol or medicine (opioid analgesics).
- Pregnant or breastfeeding women.
On the study day:
- No intake of a simple analgesic in the previous 48 hours
- No headache in the previous 48 hours
Contacts and LocationsPlease refer to this study by its ClinicalTrials.gov identifier: NCT00358839
| Denmark | |
| Danish Headache Center | |
| Glostrup, Copenhagen, Denmark, 2600 | |
| Principal Investigator: | Jakob Møller Hansen, MD | Danish Headache Center |
More Information
| ClinicalTrials.gov Identifier: | NCT00358839 History of Changes |
| Other Study ID Numbers: |
FHM-CGRP |
| Study First Received: | July 31, 2006 |
| Last Updated: | November 9, 2006 |
Keywords provided by Danish Headache Center:
|
Familial hemiplegic migraine type 1 and 2 CGRP middle cerebral artery superficial temporal artery |
headache genotype Healthy Volunteers |
Additional relevant MeSH terms:
|
Migraine Disorders Headache Migraine with Aura Headache Disorders, Primary Headache Disorders Brain Diseases Central Nervous System Diseases Nervous System Diseases Pain |
Neurologic Manifestations Signs and Symptoms Salmon calcitonin Calcitonin Calcitonin Gene-Related Peptide Bone Density Conservation Agents Physiological Effects of Drugs Vasodilator Agents |
ClinicalTrials.gov processed this record on July 21, 2017